BR112022011364A2 - Compostos para tratar disautonomia familiar - Google Patents

Compostos para tratar disautonomia familiar

Info

Publication number
BR112022011364A2
BR112022011364A2 BR112022011364A BR112022011364A BR112022011364A2 BR 112022011364 A2 BR112022011364 A2 BR 112022011364A2 BR 112022011364 A BR112022011364 A BR 112022011364A BR 112022011364 A BR112022011364 A BR 112022011364A BR 112022011364 A2 BR112022011364 A2 BR 112022011364A2
Authority
BR
Brazil
Prior art keywords
compounds
dysautonomia
family
treat
present disclosure
Prior art date
Application number
BR112022011364A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhang Nanjing
A Arnold Michael
Dakka Amal
Mitchell Karp Gary
Tuan LUONG Tom
Morrill Christie
Narasimhan Jana
A Naryshkin Nikolai
Turpoff Anthony
Wang Jiashi
Zhang Xiaoyan
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of BR112022011364A2 publication Critical patent/BR112022011364A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
BR112022011364A 2019-12-12 2020-12-07 Compostos para tratar disautonomia familiar BR112022011364A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947049P 2019-12-12 2019-12-12
PCT/US2020/063612 WO2021118929A1 (en) 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
BR112022011364A2 true BR112022011364A2 (pt) 2022-08-23

Family

ID=74046197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011364A BR112022011364A2 (pt) 2019-12-12 2020-12-07 Compostos para tratar disautonomia familiar

Country Status (14)

Country Link
US (1) US20230057568A1 (enExample)
EP (1) EP4072677A1 (enExample)
JP (2) JP2023506488A (enExample)
KR (1) KR20220113700A (enExample)
CN (1) CN115209955A (enExample)
AU (1) AU2020402717A1 (enExample)
BR (1) BR112022011364A2 (enExample)
CA (1) CA3160053A1 (enExample)
CL (1) CL2022001523A1 (enExample)
CO (1) CO2022008195A2 (enExample)
IL (1) IL293764A (enExample)
MX (1) MX428411B (enExample)
PE (1) PE20221581A1 (enExample)
WO (1) WO2021118929A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP2024533264A (ja) * 2021-09-07 2024-09-12 ピーティーシー セラピューティクス， インコーポレイテッド 神経原性疾患を処置するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005007083A2 (en) * 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
US20130317045A1 (en) * 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103242341B (zh) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
CA3199430A1 (en) * 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CN110312528B (zh) * 2017-02-20 2022-02-18 国立大学法人京都大学 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
AU2020222881C1 (en) * 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) * 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
KR20220113700A (ko) 2022-08-16
CO2022008195A2 (es) 2022-07-29
CL2022001523A1 (es) 2023-03-31
US20230057568A1 (en) 2023-02-23
EP4072677A1 (en) 2022-10-19
PE20221581A1 (es) 2022-10-06
MX2022007094A (es) 2022-07-11
AU2020402717A1 (en) 2022-06-23
CN115209955A (zh) 2022-10-18
WO2021118929A1 (en) 2021-06-17
JP2023506488A (ja) 2023-02-16
JP2025133750A (ja) 2025-09-11
CA3160053A1 (en) 2021-06-17
MX428411B (es) 2025-11-13
IL293764A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MX2021009667A (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
BR112012012815A8 (pt) composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica
MX2022007094A (es) Compuestos para tratar la disautonomía familiar.
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR112021023359A2 (pt) Inibidores de g12c de kras e usos dos mesmos
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
BRPI1006602A2 (pt) composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
BR112019007144A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
MX385562B (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
BR112016024626A8 (pt) compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112014017650A8 (pt) Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
EA201201191A1 (ru) 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
CO2020015377A2 (es) Moduladores de la expresión de apol1
EA201891115A1 (ru) Новая фармацевтическая композиция, содержащая частицы, содержащие комплекс двухнитевого полирибонуклеотида и полиалкиленимина
BR112012013888A2 (pt) preparados de combinação com antagonista de citocina e corticosteroide
BR112022011147A2 (pt) Compostos para inibir fatores de neovascularização e uso dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]